• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Bausch Health Companies Inc. (Amendment)

    2/7/24 9:00:18 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BHC alert in real time by email
    SC 13D/A 1 n2779_x197-sc13da.htm SC 13D/A

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No.4)*

     

    Bausch Health Companies Inc.
    (Name of Issuer)

     

    Common Stock, no par value
    (Title of Class of Securities)

     

    071734107

    (CUSIP Number)

     

    Jesse A. Lynn, Esq.

    Icahn Capital LP
    16690 Collins Avenue

    Sunny Isles Beach, FL 33160
    (305) 422-4100

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    February 5, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Section 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box / /.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

       

     

    SCHEDULE 13D

     

    CUSIP No. 071734107

     

     

    1.                    NAME OF REPORTING PERSON
    Icahn Partners Master Fund LP

     

    2                    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  / /

    (b)  / /

     

    3                    SEC USE ONLY

     

    4                    SOURCE OF FUNDS
    WC

     

    5                    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

     

    6                    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    7                    SOLE VOTING POWER

    14,423,595

     

    8                    SHARED VOTING POWER
    0

     

    9                    SOLE DISPOSITIVE POWER

    14,423,595

     

    10                    SHARED DISPOSITIVE POWER
    0

     

    11                   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    14,423,595

     

    12                   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

     

    13                    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    3.95%

     

    14                    TYPE OF REPORTING PERSON
    PN

     

       

     

    SCHEDULE 13D

     

    CUSIP No. 071734107

     

     

    1.                   NAME OF REPORTING PERSON
    Icahn Offshore LP

     

    2                    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  / /

    (b)  / /

     

    3                    SEC USE ONLY

     

    4                    SOURCE OF FUNDS
    OO

     

    5                    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

     

    6                    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    7                    SOLE VOTING POWER
    0

     

    8                    SHARED VOTING POWER

    14,423,595

     

    9                    SOLE DISPOSITIVE POWER
    0

     

    10                    SHARED DISPOSITIVE POWER

    14,423,595

     

    11                   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    14,423,595

     

    12                   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

     

    13                    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    3.95%

     

    14                    TYPE OF REPORTING PERSON
    PN

     

       

     

    SCHEDULE 13D

     

    CUSIP No. 071734107

     

     

    1.                   NAME OF REPORTING PERSON
    Icahn Partners LP

     

    2                    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  / /

    (b)  / /

     

    3                    SEC USE ONLY

     

    4                    SOURCE OF FUNDS
    WC

     

    5                    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

     

    6                    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    7                    SOLE VOTING POWER

    20,297,523

     

    8                    SHARED VOTING POWER
    0

     

    9                    SOLE DISPOSITIVE POWER

    20,297,523

     

    10                    SHARED DISPOSITIVE POWER
    0

     

    11                   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    20,297,523

     

    12                   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

     

    13                    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    5.56%

     

    14                    TYPE OF REPORTING PERSON
    PN

     

       

     

    SCHEDULE 13D

     

    CUSIP No. 071734107

     

     

    1.                   NAME OF REPORTING PERSON
    Icahn Onshore LP

     

    2                    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  / /

    (b)  / /

     

    3                    SEC USE ONLY

     

    4                    SOURCE OF FUNDS
    OO

     

    5                    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

     

    6                    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    7                    SOLE VOTING POWER
    0

     

    8                    SHARED VOTING POWER

    20,297,523

     

    9                    SOLE DISPOSITIVE POWER
    0

     

    10                    SHARED DISPOSITIVE POWER

    20,297,523

     

    11                   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    20,297,523

     

    12                   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

     

    13                    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    5.56%

     

    14                    TYPE OF REPORTING PERSON PN

     

       

     

    SCHEDULE 13D

     

    CUSIP No. 071734107

     

     

    1.                   NAME OF REPORTING PERSON
    Icahn Capital LP

     

    2                    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  / /

    (b)  / /

     

    3                    SEC USE ONLY

     

    4                    SOURCE OF FUNDS
    OO

     

    5                    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

     

    6                    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    7                    SOLE VOTING POWER
    0

     

    8                    SHARED VOTING POWER

    34,721,118

     

    9                    SOLE DISPOSITIVE POWER
    0

     

    10                    SHARED DISPOSITIVE POWER

    34,721,118

     

    11                   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    34,721,118

     

    12                   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

     

    13                    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.51%

     

    14                    TYPE OF REPORTING PERSON
    PN

     

     

       

     

    SCHEDULE 13D

     

    CUSIP No. 071734107

     

     

    1.                   NAME OF REPORTING PERSON
    IPH GP LLC

     

    2                    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  / /

    (b)  / /

     

    3                    SEC USE ONLY

     

    4                    SOURCE OF FUNDS
    OO

     

    5                    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

     

    6                    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    7                    SOLE VOTING POWER
    0

     

    8                    SHARED VOTING POWER

    34,721,118

     

    9                    SOLE DISPOSITIVE POWER
    0

     

    10                    SHARED DISPOSITIVE POWER

    34,721,118

     

    11                   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    34,721,118

     

    12                   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

     

    13                    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.51%

     

    14                    TYPE OF REPORTING PERSON
    OO

     

       

     

    SCHEDULE 13D

     

    CUSIP No. 071734107

     

     

    1.                   NAME OF REPORTING PERSON
    Icahn Enterprises Holdings L.P.

     

    2                    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  / /

    (b)  / /

     

    3                    SEC USE ONLY

     

    4                    SOURCE OF FUNDS
    OO

     

    5                    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

     

    6                    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    7                    SOLE VOTING POWER
    0

     

    8                    SHARED VOTING POWER

    34,721,118

     

    9                    SOLE DISPOSITIVE POWER
    0

     

    10                    SHARED DISPOSITIVE POWER

    34,721,118

     

    11                   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    34,721,118

     

    12                   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

     

    13                    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.51%

     

    14                    TYPE OF REPORTING PERSON
    PN

     

       

     

    SCHEDULE 13D

     

    CUSIP No. 071734107

     

     

    1.                   NAME OF REPORTING PERSON
    Icahn Enterprises G.P. Inc.

     

    2                    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  / /

    (b)  / /

     

    3                    SEC USE ONLY

     

    4                    SOURCE OF FUNDS
    OO

     

    5                    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

     

    6                    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    7                    SOLE VOTING POWER
    0

     

    8                    SHARED VOTING POWER

    34,721,118

     

    9                    SOLE DISPOSITIVE POWER
    0

     

    10                    SHARED DISPOSITIVE POWER

    34,721,118

     

    11                   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    34,721,118

     

    12                   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

     

    13                    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.51%

     

    14                    TYPE OF REPORTING PERSON
    CO

     

       

     

    SCHEDULE 13D

     

    CUSIP No. 071734107

     

     

    1.                   NAME OF REPORTING PERSON
    Beckton Corp.

     

    2                    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  / /

    (b)  / /

     

    3                    SEC USE ONLY

     

    4                    SOURCE OF FUNDS
    OO

     

    5                    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

     

    6                    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    7                    SOLE VOTING POWER
    0

     

    8                    SHARED VOTING POWER

    34,721,118

     

    9                    SOLE DISPOSITIVE POWER
    0

     

    10                    SHARED DISPOSITIVE POWER

    34,721,118

     

    11                   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    34,721,118

     

    12                   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

     

    13                    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.51%

     

    14                    TYPE OF REPORTING PERSON
    CO

     

       

     

    SCHEDULE 13D

     

    CUSIP No. 071734107

     

     

    1                    NAME OF REPORTING PERSON
    Carl C. Icahn

     

    2                    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  / /

    (b)  / /

     

    3                    SEC USE ONLY

     

    4                    SOURCE OF FUNDS
    OO

     

    5                    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

     

    6                    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    7                    SOLE VOTING POWER
    0

     

    8                    SHARED VOTING POWER

    34,721,118

     

    9                    SOLE DISPOSITIVE POWER
    0

     

    10                    SHARED DISPOSITIVE POWER

    34,721,118

     

    11                   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    34,721,118

     

    12                   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

     

    13                    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.51%

     

    14                    TYPE OF REPORTING PERSON
    IN

     

       

     

    SCHEDULE 13D

     

    This Amendment No. 4 amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on February 11, 2021 relating to the Reporting Persons’ interests in the Shares of the Issuer (as previously amended, the “Schedule 13D”), for the purpose of complying with the SEC’s amended disclosure requirements under Item 6 of Schedule 13D, effective as of February 5, 2024, and providing certain other non-material updated information as of February 5, 2024 as set forth herein. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.

     

    Item 3. Source and Amount of Funds or Other Consideration

     

    Item 3 of the Schedule 13D is hereby amended by replacing it in its entirety with the following:

     

    The Reporting Persons may be deemed to be the beneficial owner of, in the aggregate, 34,721,118 Shares, which were purchased by the Reporting Persons for an aggregate purchase price of approximately $932 million.

     

    The source of funding for the Shares held by the Reporting Persons was the general working capital of the respective purchasers. The Shares held by the Reporting Persons are held in margin accounts together with other securities. Such margin accounts may from time to time have debit balances. Part of the purchase price for such Shares was obtained through margin borrowing.

     

    Item 5. Interest in Securities of the Issuer

     

    Items 5(a), (b) and (c) of the Schedule 13D are hereby amended by replacing them in their entirety with the following:

     

    (a) The Reporting Persons may be deemed to beneficially own, in the aggregate, 34,721,118 Shares, representing approximately 9.51% of the Issuer's outstanding Shares (based on the 365,195,048 Shares outstanding as of October 27, 2023, as reported by the Issuer in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2023).

     

    (b) Icahn Master has sole voting power and sole dispositive power with regard to 14,423,595 Shares. Each of Icahn Offshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn has shared voting power and shared dispositive power with regard to such Shares. Icahn Partners has sole voting power and sole dispositive power with regard to 20,297,523 Shares. Each of Icahn Onshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn has shared voting power and shared dispositive power with regard to such Shares.

     

    Each of Icahn Offshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn, by virtue of their relationships to Icahn Master (as disclosed in Item 2 of the Schedule 13D), may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Act”)) the Shares which Icahn Master directly beneficially owns. Each of Icahn Offshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn disclaims beneficial ownership of such Shares for all other purposes. Each of Icahn Onshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn, by virtue of their relationships to Icahn Partners (as disclosed in Item 2 of the Schedule 13D), may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Act) the Shares which Icahn Partners directly beneficially owns. Each of Icahn Onshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn disclaims beneficial ownership of such Shares for all other purposes.

     

    (c) The Reporting Persons have not effected any transactions with respect to the Shares during the past sixty (60) days.

     

    Item 6. Contracts, Arrangements, Understandings or Relationship with Respect to Securities of the Issuer

    Item 6 of the Schedule 13D is hereby amended by replacing it in its entirety with the following:

     

     

    The information set forth in Item 4 of the Schedule 13D regarding the Agreement is incorporated herein by reference.

     

    One or more of the Reporting Persons are party to cash-settled equity swap agreements with Nomura Global Financial Products Inc. (the “Broker”) with respect to the Shares, with reference prices and maturity dates that vary depending upon the terms of each such cash-settled equity swap agreement. Such cash-settled equity swap agreements, taken together, result in increased economic exposure of the Reporting Persons to changes in the value of the Shares during

       

     

    the period that such cash-settled equity swap agreements are in effect, and pursuant to the cash-settled equity swap agreements, either (i) the Reporting Persons will be obligated to pay to the Broker, in cash, a specified amount calculated in accordance with the terms of the applicable cash-settled equity swap agreement, which such amount will be based upon a decrease in value of the Shares between the date of the applicable cash-settled equity swap agreement and the maturity date set forth therein or (ii) the Broker will be obligated to pay to the Reporting Persons, in cash, a specified amount calculated in accordance with the terms of the applicable cash-settled equity swap agreement, which such amount will be based upon an increase in value of the Shares between the date of the applicable cash-settled equity swap agreement and the maturity date set forth therein. 

     

    In addition, one or more of the Reporting Persons may from time to time enter into one or more additional cash-settled equity swap agreements with the Broker, or with other third parties, that result in a further increase in the economic exposure of the Reporting Persons to changes in the value of the Shares, or that result in a decrease in the economic exposure of the Reporting Persons to changes in the value of the Shares, and which could require either that the Reporting Persons will be obligated to pay to the Broker or other third parties, in cash, or the Broker or other third parties will be required to pay to the Reporting Persons, in cash, an amount based upon a decrease or increase, as applicable, in the value of the Shares between the date of the applicable cash-settled equity swap agreement and the maturity date set forth therein. 

     

    Except as otherwise described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 of the Schedule 13D and between such persons and any person with respect to any securities of the Issuer, including any class of the Issuer’s securities used as a reference security, in connection with any call options, put options, security-based swaps or any other derivative securities, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

     

     

       

     

    SIGNATURE

     

    After reasonable inquiry and to the best of each of the undersigned knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 7, 2024

     

    ICAHN PARTNERS MASTER FUND LP

    ICAHN OFFSHORE LP

    ICAHN PARTNERS LP

    ICAHN ONSHORE LP

    ICAHN CAPITAL LP

     

    By:/s/ Jesse Lynn

    Name: Jesse Lynn
    Title: Chief Operating Officer

     

    IPH GP LLC

    By: Icahn Enterprises Holdings L.P., its sole member
    By: Icahn Enterprises G.P. Inc., its general partner

    ICAHN ENTERPRISES HOLDINGS L.P.

    By: Icahn Enterprises G.P. Inc., its general partner
    ICAHN ENTERPRISES G.P. INC.

     

    By:/s/ Ted Papapostolou

    Name: Ted Papapostolou
    Title: Chief Financial Officer

     

    BECKTON CORP.

     

    By:/s/ Ted Papapostolou

    Name: Ted Papapostolou
    Title: Vice President

     

    /s/ Carl C. Icahn
    Carl C. Icahn

     

     

    [Signature Page of Schedule 13D - Bausch Health Companies Inc.]

     

       

    Get the next $BHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHC

    DatePrice TargetRatingAnalyst
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    7/10/2024$8.00Mkt Perform
    Raymond James
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    6/16/2023Outperform → Market Perform
    TD Cowen
    7/29/2022Buy → Hold
    Truist
    7/29/2022$12.00 → $5.00Outperform → Sector Perform
    RBC Capital Mkts
    7/28/2022Overweight → Neutral
    JP Morgan
    6/13/2022$12.00Overweight
    JP Morgan
    More analyst ratings

    $BHC
    Leadership Updates

    Live Leadership Updates

    See more
    • Bausch Health Appoints New Chief Medical Officer and Head of R&D

      LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

      12/2/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Welcomes Two New Members to the Executive Leadership Team

      LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm

      7/19/24 7:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day

      BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition."OIC Awareness Day will help bridge the gap between healthcare providers (HCPs), patients, and caregivers by providing

      12/5/23 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bausch Health downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

      8/2/24 7:25:50 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on Bausch Health with a new price target

      Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00

      7/10/24 8:35:33 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health upgraded by Jefferies with a new price target

      Jefferies upgraded Bausch Health from Hold to Buy and set a new price target of $16.00 from $9.00 previously

      9/20/23 7:27:08 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wechsler Amy B was granted 1,062 shares, increasing direct ownership by 0.51% to 209,008 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      4/1/25 4:36:45 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Icahn Brett was granted 5,119 shares, increasing direct ownership by 3% to 161,899 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      4/1/25 4:35:23 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Paulson John was granted 9,659 shares, increasing direct ownership by 4% to 277,708 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      4/1/25 4:34:05 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    SEC Filings

    See more
    • Bausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bausch Health Companies Inc. (0000885590) (Filer)

      4/30/25 4:11:13 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Bausch Health Companies Inc.

      DEFA14A - Bausch Health Companies Inc. (0000885590) (Filer)

      4/22/25 7:00:33 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form CERT filed by Bausch Health Companies Inc.

      CERT - Bausch Health Companies Inc. (0000885590) (Filer)

      4/17/25 9:29:12 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program

      LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program.We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN® delivers for the healthcare system in addition to sharing recommendations from The American Assoc

      1/17/25 9:25:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

      LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO):"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is

      12/12/24 7:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day

      LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support t

      12/5/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Financials

    Live finance-specific insights

    See more
    • Bausch Health Announces Third Quarter 2024 Results

      Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segmentsConsolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $909 million, up 10%Raising full-year 2024 guidance LAVAL, QC / ACCESSWIRE / October 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2024 financial results and other key updates fro

      10/30/24 4:05:00 PM ET
      $BHC
      $NHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Hospital/Nursing Management
    • Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

      LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Wednesday, October 30, 2024Time:5:00 p.m. U.S. ESTWebcast:https://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in t

      10/9/24 4:05:00 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Announces Second Quarter 2024 Results

      Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10%Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter."We continued our momentum in the second quarter, delivering our fifth

      7/31/24 12:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bausch Health Companies Inc.

      SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

      8/30/24 6:12:52 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Bausch Health Companies Inc.

      SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

      8/19/24 5:48:41 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bausch Health Companies Inc. (Amendment)

      SC 13G/A - Bausch Health Companies Inc. (0000885590) (Subject)

      2/13/24 4:30:26 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care